Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017090058) FUSED PYRIMIDINES AS ISOFORM SELECTIVE PHOSPHOINOSITIDE-3-KINASE-ALPHA INHIBITORS AND PROCESS FOR PREPARATION THEREOF
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/090058 International Application No.: PCT/IN2016/050416
Publication Date: 01.06.2017 International Filing Date: 21.11.2016
IPC:
C07D 491/147 (2006.01) ,C07D 495/04 (2006.01) ,A61K 31/519 (2006.01) ,A61K 31/5377 (2006.01) ,A61P 35/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
491
Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/-C07D459/290
12
in which the condensed system contains three hetero rings
14
Ortho-condensed systems
147
the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
495
Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519
ortho- or peri-condensed with heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
535
having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
5375
1,4-Oxazines, e.g. morpholine
5377
not condensed and containing further heterocyclic rings, e.g. timolol
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH [IN/IN]; Anusandhan Bhawan, Rafi Marg New Delhi 110001, IN
Inventors:
BHARATE, Sandip Bibishan; IN
BHUSHAN, Shashi; IN
MOHAMMED, Shabber; IN
GURU, Santosh Kumar; IN
BHARATE, Sonali Sandip; IN
KUMAR, Vikas; IN
MAHAJAN, Girish; IN
MINTOO, Mubashir Javed; IN
MONDHE, Dilip Manikrao; IN
VISHWAKARMA, Ram; IN
Agent:
SINHG, Manisha; IN
Priority Data:
3818/DEL/201523.11.2015IN
Title (EN) FUSED PYRIMIDINES AS ISOFORM SELECTIVE PHOSPHOINOSITIDE-3-KINASE-ALPHA INHIBITORS AND PROCESS FOR PREPARATION THEREOF
(FR) PYRIMIDINES FUSIONNÉES UTILISÉES COMME INHIBITEURS DE LA PHOSPHOINOSITIDE 3-KINASE ALPHA SÉLECTIFS D'UNE ISOFORME ET LEUR PROCÉDÉ DE PRÉPARATION
Abstract:
(EN) The present invention relates to fused pyrimidines of formulae I and II wherein, R1, R2 are as herein described. The present invention particularly relates to isoform selective PI3Kα inhibition and their medicinal use as anticancer agents.
(FR) La présente invention concerne des pyrimidines fusionnées représentées par les formules I et II, dans lesquelles R1, R2 sont tels que décrits dans la description. La présente invention concerne en particulier des inhibiteurs de la PI3Kα sélectifs d'une isoforme et leur utilisation thérapeutique comme agents anticancéreux.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
CA3004534EP3380476